Several studies have identified increases in NGAL in subjects with familial amyloid polyneuropathy [68] and more recently in patients with late-life depression [69-71], Down’s syndrome with dementia [72], and Alzheimer’s disease with depression [73]. This evidence concerns the gene LCN2 and depressive symptom measurement.